![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
I Lucki, HR Ward and A Frazer
Department of Psychiatry, University of Pennsylvania, Philadelphia.
The piperazine-type 5-hydroxytryptamine (5-HT) agonists 1-(m- trifluoromethylphenyl)piperazine (TFMPP), 1-(m-chlorophenyl)-piperazine (m-CPP), 1-(p-chlorophenyl)piperazine (p-CPP) and MK-212 [6-chloro-2-(1- piperazinyl)pyrazine], produced a dose-dependent suppression of spontaneous ambulatory behavior in rats. Pretreatment with the 5-HT antagonists metergoline, methysergide or mianserin, but not selective 5- HT2 or catecholamine antagonists, blocked the reduction of activity caused by TFMPP suggesting that the stimulation of 5-HT receptors was involved in causing this behavioral effect. Other behavioral signs of 5- HT receptor stimulation, such as the 5-HT behavioral syndrome or head- shaking behavior, were not observed in rats injected with TFMPP, m-CPP or MK-212 except at toxic doses. The ability of piperazine agonists to reduce locomotor activity in rats was altered by long-term changes in 5- HT neurotransmission. The destruction of 5-HT neurons by i.v.t. injection of the neurotoxin 5,7-dihydroxytryptamine potentiated the ability of m-CPP to inhibit ambulatory behavior. On the other hand, elevating 5-HT content by administering the monoamine oxidase inhibitors phenelzine or nialamide for 7 days reduced the ability of m- CPP to suppress locomotor activity. Acute administration of the monoamine oxidase inhibitors, or chronic administration of other antidepressants such as desmethylimipramine or iprindole, failed to alter m-CPPs activity-suppressant effects. These studies suggest that chronic changes in 5-HT neurotransmission produce compensatory changes which alter the behavioral response to these piperazine agonists. Taken together with other evidence that both TFMPP and m-CPP are agonists at 5-HT1B and 5-HT1C receptors, the effects of TFMPP and m-CPP on locomotor activity may be associated with the selective activation of 5- HT1C, or possibly 5-HT1B, receptors.
This article has been cited by other articles:
|
|
 |
|
  J- M Nothias, T. Mitsui, J. S. Shumsky, I. Fischer, M. D. Antonacci, and M. Murray Combined Effects of Neurotrophin Secreting Transplants, Exercise, and Serotonergic Drug Challenge Improve Function in Spinal Rats Neurorehabil Neural Repair, December 1, 2005; 19(4): 296 - 312. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Filip and K. A. Cunningham Hyperlocomotive and Discriminative Stimulus Effects of Cocaine Are Under the Control of Serotonin2C (5-HT2C) Receptors in Rat Prefrontal Cortex J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 734 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nadeson and C. S. Goodchild Antinociceptive role of 5-HT1A receptors in rat spinal cord Br. J. Anaesth., May 1, 2002; 88(5): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Bankson and K. A. Cunningham 3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 846 - 852. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. Cryan and I. Lucki Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2C Receptors J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1120 - 1126. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. E. Pickard, B. N. Smith, M. Belenky, M. A. Rea, F. E. Dudek, and P. J. Sollars 5-HT1B Receptor-Mediated Presynaptic Inhibition of Retinal Input to the Suprachiasmatic Nucleus J. Neurosci., May 15, 1999; 19(10): 4034 - 4045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Vanecek, W. D. Essman, D. P. Taylor, and J. H. Woods Discriminative Stimulus Characteristics of BMY 14802 in the Pigeon J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 1 - 9. [Abstract] [Full Text]
|
|
|
|
|
|
A. Kulikov, S. Aguerre, O. Berton, A. Ramos, P. Mormede, and F. Chaouloff Central Serotonergic Systems in the Spontaneously Hypertensive and Lewis Rat Strains that Differ in the Elevated Plus-Maze Test of Anxiety J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 775 - 784. [Abstract] [Full Text]
|
|
|
|
|
|
G. E. Pickard, E. T. Weber, P. A. Scott, A. F. Riberdy, and M. A. Rea 5HT1B Receptor Agonists Inhibit Light-Induced Phase Shifts of Behavioral Circadian Rhythms and Expression of the Immediate-Early Gene c-fos in the Suprachiasmatic Nucleus J. Neurosci., December 15, 1996; 16(24): 8208 - 8220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Becamel, A. Figge, S. Poliak, A. Dumuis, E. Peles, J. Bockaert, H. Lubbert, and C. Ullmer Interaction of Serotonin 5-Hydroxytryptamine Type 2C Receptors with PDZ10 of the Multi-PDZ Domain Protein MUPP1 J. Biol. Chem., April 13, 2001; 276(16): 12974 - 12982. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
